Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
about
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcomeMolecular aspects of prostate cancer with neuroendocrine differentiationNeuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failureProstate cancer and parasitism of the bone hematopoietic stem cell nicheThe dual regulatory role of miR-204 in cancerSYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 proteinA dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cellsPrognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancerCD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells.Targeting unique metabolic properties of breast tumor initiating cellsThe dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.Prostate cancer cell lines under hypoxia exhibit greater stem-like properties.Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cellsEpcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability.Prostate cancer stem cell biology.PC3 is a cell line characteristic of prostatic small cell carcinoma.Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine CarcinomaBlood and tissue biomarkers in prostate cancer: state of the art.Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancerPyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers.Upregulation of FAM84B during prostate cancer progression.The Roles of MicroRNAs in the Cancer Invasion-Metastasis CascadeProstate cancer stem cells and their potential roles in metastasis.Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines.Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis.Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations.SOX2 expression in the developing, adult, as well as, diseased prostatePotential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
P2860
Q24631043-8079360B-B245-4561-AC32-68CFC41F3967Q26752910-5A31AB24-4A40-498B-864E-1312945E5EB4Q26859201-97623E45-AED8-445A-818F-0B2F5E258A77Q26996231-54100566-BE2D-4E7B-87EE-86D07B7974E9Q28078421-A1848D35-A6ED-45FB-BEED-23E9008AAF6FQ28568099-D0FA0AC9-D45E-40D2-81F8-15A85E35DD35Q28573536-16E0FDDF-E465-4B5C-AF88-C017D69C446DQ33356928-2CAA6996-D4AC-4700-AC68-0F855C72B47AQ33523906-4A654144-06B5-43B4-BB2B-2037EBB26774Q33689071-BB8C831D-48EA-4FFC-843A-762F5A8E99EAQ33793473-C00DE493-FBDE-40A4-A199-BE8B6779504DQ34089425-BBA8A722-CA55-4C43-B163-B578088588C2Q34105402-369DBE47-565F-439A-9603-67AB0A6A8C50Q34117287-541D34B4-A94A-47B3-973A-B6CE7055975CQ34126555-04C461DD-0F9D-4D8C-BEF3-CC8921DB72D4Q34238517-223DB4C5-CF60-4DD8-83FD-FDA2D8677FC7Q35903584-59F3C71C-7AF2-4E78-8096-3B547E1F0056Q36185201-761EF2EF-E9ED-48FB-AF4E-7FB4F3DA2A5DQ36206304-28FAA232-0B82-4126-B2B2-2840D6D8E3F9Q36490023-12B58662-8B52-490D-AA07-3CF1697DA866Q36805567-ACB9ABAA-49D2-4DA3-B9D9-66DAD1C9A7C2Q37201929-3B7F804F-805C-4815-B434-9A4A8AD81A49Q37403008-706BCFE5-8241-4CE4-A4E7-A9C923B8E573Q37683681-1A219233-AA0A-412F-B95C-3A2F4658DDCFQ37706613-5CEAF1A1-11AA-4083-8D9D-3F5FD68879B9Q37745966-D8C91D6C-B34C-4C5F-9375-72E55D42887AQ37826351-2811887B-2754-48FC-B03C-9E9A846A9788Q37863626-25E3A1A2-49DC-487D-A851-1D88A107CAD3Q37882512-9F2347C7-8B59-43F5-9462-E14F231F3164Q38209356-BD2728D0-AC8A-42AB-B4CA-40A026EC2FDCQ38643148-A21AAACE-2020-498E-98BE-CE70C8EF2ADDQ38807901-681484D4-0098-4521-9063-B61A1477FA28Q38952586-002B5C4D-8D8D-4369-AA40-3A16BA28D7A4Q39208225-EDF78F51-3DAD-41DB-8D14-D46BAB2D3858Q39410915-E3974D4A-7947-4A41-86EA-F48E6C371C60Q39424549-25F9FC49-8D8C-45BE-A313-684F920882EDQ42112184-490C9CD9-AF7E-4B9B-98FB-BD2B27E0960DQ42463444-8C77117D-6CCF-4420-8C38-4655B2F2CDB8Q43623151-F45FA2AA-CC4E-4674-96AD-F6F45DE4621FQ46569075-0D85C84F-6C7C-4D46-A465-01067CA198A9
P2860
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Selective expression of CD44, ...... ells of human prostate cancer.
@en
type
label
Selective expression of CD44, ...... ells of human prostate cancer.
@en
prefLabel
Selective expression of CD44, ...... ells of human prostate cancer.
@en
P2093
P356
P1433
P1476
Selective expression of CD44, ...... ells of human prostate cancer.
@en
P2093
Chengyu Wu
Christopher R Silvers
Ganesh S Palapattu
Heather B Martin
Jiaoti Huang
Karin Williams
Li-Shan Huang
Linda Salamone
Timothy Bushnell
P304
P356
10.1002/PROS.20928
P577
2009-05-01T00:00:00Z